Brainomix Ltd. completes £14m Series C financing

Brainomix  Ltd.’s Series C financing was co-led by UK’s Parkwalk Advisors, and the Boehringer Ingelheim Venture Fund (BIVF), along with Australian pension fund Hostplus. The round was supported by LifeSci Capital.

Brainomix has pioneered the development of an AI platform that automates the identification of validated imaging biomarkers to improve both diagnosis and treatment decisions. Its NICE-endorsed technology that has been deployed to more than 300 hospitals and more than 1.5 million patients. Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, a life-changing stroke treatment reducing disability.

Brainomix states the new funding will accelerate its commercial expansion into the US, where the company has recently secured ten FDA clearances. Fresh funding will also support Brainomix to advance its portfolio of AI-powered technology in new areas with limited treatment options such as lung fibrosis. Brainomix plans to expand both its Oxford-based operations and global commercial team.

Brainomix has already applied its AI solution to pulmonary fibrosis, with the development and FDA clearance of its Brainomix 360 e-Lung technology to accurately predict the progression of the disease. The company has an ongoing partnership with Boehringer Ingelheim, a leading developer of  lung fibrosis treatments, to evaluate the real-world impact of e-Lung to improve the identification and access to treatment for people with progressive lung fibrosis.